Life Science Investing ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer 16 December
Life Science Investing Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 05 November
Life Science Investing FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone 28 August
